Chemistry-based functional proteomics for drug target deconvolution

Expert Review of Proteomics

Volumn 9, Issue 3, 2012, Pages 293-310

  Wang, Kui ^a   Yang, Tao ^a   Wu, Qian ^a   Zhao, Xia ^a   Nice, Edouard Collins ^b   Huang, Canhua ^a  

^a SICHUAN UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

ABPP; affinity chromatography; CCCP; chemistry based functional proteomics; target deconvolution

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BISINDOLYLMALEIMIDE; BOSUTINIB; DASATINIB; DIAZONAMIDE A; DRUG; GEFITINIB; IMATINIB; NILOTINIB; ORANTINIB; PATEAMINE A; PLADIENOLIDE; QUINOLINE DERIVATIVE; ROSCOVITINE; THALIDOMIDE; UNCLASSIFIED DRUG;

ACTIVITY BASED PROTEIN PROFILING; COMPOUND CENTRIC CHEMICAL PROTEOMICS; DRUG TARGETING; GENOMICS; HUMAN; NONHUMAN; PROTEOMICS; REVIEW;

BIOTIN; CHROMATOGRAPHY, AFFINITY; CLICK CHEMISTRY; DRUG DISCOVERY; ENZYMES; FLUORESCENT DYES; HUMANS; MOLECULAR PROBES; PROTEIN BINDING; PROTEINS; PROTEOMICS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864230853     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.19     Document Type: Review

References (151)

1. Sams-Dodd F. Target-based drug discovery: Is something wrong? Drug Discov. Today 10(2), 139-147 (2005).
2. Falconer SB, Brown ED. New screens and targets in antibacterial drug discovery. Curr. Opin. Microbiol. 12(5), 497-504 (2009).
3. Terstappen GC, Schlüpen C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6(11), 891-903 (2007).
4. Saxena C, Higgs RE, Zhen E, Hale JE. Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution. Expert Opin. Drug Discov. 4(7), 701-714 (2009).
5. Raida M. Drug target deconvolution by chemical proteomics. Curr. Opin. Chem. Biol. 15(4), 570-575 (2011).
6. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431(7011), 931-945 (2004).
7. Reiss T. Drug discovery of the future: The implications of the human genome project. Trends Biotechnol. 19(12), 496-499 (2001).
8. Lander ES. Initial impact of the sequencing of the human genome. Nature 470(7333), 187-197 (2011).
9. Verhelst SH, Bogyo M. Chemical proteomics applied to target identification and drug discovery. BioTechniques 38(2), 175-177 (2005).
10. Jeffery DA, Bogyo M. Chemical proteomics and its application to drug discovery. Curr. Opin. Biotechnol. 14(1), 87-95 (2003).
11. Kolch W, Pitt A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10(9), 618-629 (2010).
12. Liu R, Wang K, Yuan K, Wei Y, Huang C. Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev. Proteomics 7(3), 411-429 (2010).
13. Wong SC, Chan CM, Ma BB et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev. Proteomics 6(2), 123-134 (2009).
14. Zhao Y, Lee WN, Xiao GG. Quantitative proteomics and biomarker discovery in human cancer. Expert Rev. Proteomics 6(2), 115-118 (2009).
15. Cowan ML, Vera J. Proteomics: Advances in biomarker discovery. Expert Rev. Proteomics 5(1), 21-23 (2008).
16. Kobe B, Kemp BE. Active site-directed protein regulation. Nature 402(6760), 373-376 (1999).
17. Jessani N, Cravatt BF. The development and application of methods for activitybased protein profiling. Curr. Opin. Chem. Biol. 8(1), 54-59 (2004).
18. Bantscheff M, Scholten A, Heck AJ. Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov. Today 14(21-22), 1021-1029 (2009).
19. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5(9), 616-624 (2009).
20. Yuan K, Lei Y, Huang C. Application of chemistry-based functional proteomics to screening for novel drug targets. Comb. Chem. High Throughput Screen. 13(5), 414-421 (2010).
21. Heal WP, Dang TH, Tate EW. Activitybased probes: Discovering new biology and new drug targets. Chem. Soc. Rev. 40(1), 246-257 (2011).
22. Barglow KT, Cravatt BF. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4(10), 822-827 (2007).
23. Sadaghiani AM, Verhelst SH, Bogyo M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11(1), 20-28 (2007).
24. Nodwell MB, Sieber SA. ABPP methodology: Introduction and overview. Top. Curr. Chem. 324, 1-41 (2012).
25. Wetzel S, Bon RS, Kumar K, Waldmann H. Biology-oriented synthesis. Angew. Chem. Int. Ed. Engl. 50(46), 10800-10826 (2011).
26. Shi H, Liu K, Xu A, Yao SQ. Small molecule microarray-facilitated screening of affinity-based probes (AfBPs) for gamma-secretase. Chem. Commun. (Camb.) 33, 5030-5032 (2009).
27. Liu K, Shi H, Xiao H et al. Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites. Angew. Chem. Int. Ed. Engl. 48(44), 8293-8297 (2009).
28. Shi H, Uttamchandani M, Yao SQ. A method for small molecule microarraybased screening for the rapid discovery of affinity-based probes. Methods Mol. Biol. 669, 57-68 (2010).
29. Shi H, Zhang CJ, Chen GY, Yao SQ. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J. Am. Chem. Soc. 134(6), 3001-3014 (2012).
30. Li YM, Xu M, Lai MT et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405(6787), 689-694 (2000).
31. Sieber SA, Niessen S, Hoover HS, Cravatt BF. Proteomic profiling of metalloprotease activities with cocktails of active-site probes. Nat. Chem. Biol. 2(5), 274-281 (2006).
32. Uttamchandani M, Li J, Sun H, Yao SQ. Activity-based protein profiling: New developments and directions in functional proteomics. Chembiochem 9(5), 667-675 (2008).
33. Paulick MG, Bogyo M. Application of activity-based probes to the study of enzymes involved in cancer progression. Curr. Opin. Genet. Dev. 18(1), 97-106 (2008).
34. Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: From enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383-414 (2008).
35. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov. Today 8(24), 1128-1137 (2003).
36. Speers AE, Adam GC, Cravatt BF. Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 125(16), 4686-4687 (2003).
37. Speers AE, Cravatt BF. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11(4), 535-546 (2004).
38. Jessani N, Liu Y, Humphrey M, Cravatt BF. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl Acad. Sci. USA 99(16), 10335-10340 (2002).
39. Chiang KP, Niessen S, Saghatelian A, Cravatt BF. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem. Biol. 13(10), 1041-1050 (2006).
40. Leung D, Hardouin C, Boger DL, Cravatt BF. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 21(6), 687-691 (2003).
41. Chang JW, Nomura DK, Cravatt BF. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. Chem. Biol. 18(4), 476-484 (2011).
42. Serwa R, Tate EW. Activity-based profiling for drug discovery. Chem. Biol. 18(4), 407-409 (2011).
43. Doucet A, Butler GS, Rodríguez D, Prudova A, Overall CM. Metadegradomics: Toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol. Cell Proteomics 7(10), 1925-1951 (2008).
44. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291(2), 113-135 (2000).
45. Leung D, Abbenante G, Fairlie DP. Protease inhibitors: Current status and future prospects. J. Med. Chem. 43(3), 305-341 (2000).
46. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10(9), 630-638 (2010).
47. Fonovic M, Bogyo M. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev. Proteomics 5(5), 721-730 (2008).
48. Heal WP, Wickramasinghe SR, Tate EW. Activity based chemical proteomics: Profiling proteases as drug targets. Curr. Drug Discov. Technol. 5(3), 200-212 (2008).
49. Liu Y, Patricelli MP, Cravatt BF. Activitybased protein profiling: The serine hydrolases. Proc. Natl Acad. Sci. USA 96(26), 14694-14699 (1999).
50. Kidd D, Liu Y, Cravatt BF. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40(13), 4005-4015 (2001).
51. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140(1), 49-61 (2010).
52. Shields DJ, Niessen S, Murphy EA et al. RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc. Natl Acad. Sci. USA 107(5), 2189-2194 (2010).
53. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7(8), 569-581 (2000).
54. Joyce JA, Baruch A, Chehade K et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5(5), 443-453 (2004).
55. Kato D, Boatright KM, Berger AB et al. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 1(1), 33-38 (2005).
56. Berger AB, Witte MD, Denault JB et al. Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol. Cell 23(4), 509-521 (2006).
57. Edgington LE, Berger AB, Blum G et al. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat. Med. 15(8), 967-973 (2009).
58. Hemelaar J, Galardy PJ, Borodovsky A, Kessler BM, Ploegh HL, Ovaa H. Chemistry-based functional proteomics: Mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res. 3(2), 268-276 (2004).
59. Kessler BM. Putting proteomics on target: Activity-based profiling of ubiquitin and ubiquitin-like processing enzymes. Expert Rev. Proteomics 3(2), 213-221 (2006).
60. Klionsky DJ, Abeliovich H, Agostinis P et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2), 151-175 (2008).
61. Hemelaar J, Lelyveld VS, Kessler BM, Ploegh HL. A single protease, Apg4B, is specific for the autophagy-related ubiquitinlike proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L. J. Biol. Chem. 278(51), 51841-51850 (2003).
62. Gareau JR, Lima CD. The SUMO pathway: Emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11(12), 861-871 (2010).
63. Hemelaar J, Borodovsky A, Kessler BM et al. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell. Biol. 24(1), 84-95 (2004).
64. Makarova KS, Aravind L, Koonin EV. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci. 25(2), 50-52 (2000).
65. Borodovsky A, Ovaa H, Kolli N et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9(10), 1149-1159 (2002).
66. Kattenhorn LM, Korbel GA, Kessler BM, Spooner E, Ploegh HL. A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family Herpesviridae. Mol. Cell 19(4), 547-557 (2005).
67. Chan EW, Chattopadhaya S, Panicker RC, Huang X, Yao SQ. Developing photoactive affinity probes for proteomic profiling: Hydroxamate-based probes for metalloproteases. J. Am. Chem. Soc. 126(44), 14435-14446 (2004).
68. Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt BF. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl Acad. Sci. USA 101(27), 10000-10005 (2004).
69. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc. Natl Acad. Sci. USA 104(4), 1171-1176 (2007).
70. Salisbury CM, Cravatt BF. Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 130(7), 2184-2194 (2008).
71. Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80, 769-795 (2011).
72. Blaskovich MA. Drug discovery and protein tyrosine phosphatases. Curr. Med. Chem. 16(17), 2095-2176 (2009).
73. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 298(5600), 1912-1934 (2002).
74. Manning G, Plowman GD, Hunter T, Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 27(10), 514-520 (2002).
75. Colman RF. Affinity labeling of purine nucleotide sites in proteins. Annu. Rev. Biochem. 52, 67-91 (1983).
76. Patricelli MP, Szardenings AK, Liyanage M et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46(2), 350-358 (2007).
77. Yee MC, Fas SC, Stohlmeyer MM, Wandless TJ, Cimprich KA. A cellpermeable, activity-based probe for protein and lipid kinases. J. Biol. Chem. 280(32), 29053-29059 (2005).
78. Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J. Biol. Chem. 282(4), 2505-2511 (2007).
79. Shreder KR, Liu Y, Nomanhboy T et al. Design and synthesis of AX7574: A microcystin-derived, fluorescent probe for serine/threonine phosphatases. Bioconjug. Chem. 15(4), 790-798 (2004).
80. Krishnamurthy D, Barrios AM. Profiling protein tyrosine phosphatase activity with mechanistic probes. Curr. Opin. Chem. Biol. 13(4), 375-381 (2009).
81. Walls C, Zhou B, Zhang ZY. Activitybased protein profiling of protein tyrosine phosphatases. Methods Mol. Biol. 519, 417-429 (2009).
82. Kumar S, Zhou B, Liang F, Wang WQ, Huang Z, Zhang ZY. Activity-based probes for protein tyrosine phosphatases. Proc. Natl Acad. Sci. USA 101(21), 7943-7948 (2004).
83. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat. Rev. Microbiol. 3(4), 281-294 (2005).
84. Blais DR, Nasheri N, McKay CS, Legault MC, Pezacki JP. Activity-based protein profiling of host-virus interactions. Trends Biotechnol. 30(2), 89-99 (2012).
85. Bernhard OK, Diefenbach RJ, Cunningham AL. New insights into viral structure and virus-cell interactions through proteomics. Expert Rev. Proteomics 2(4), 577-588 (2005).
86. Maxwell KL, Frappier L. Viral proteomics. Microbiol. Mol. Biol. Rev. 71(2), 398-411 (2007).
87. Blais DR, Brûlotte M, Qian Y, Bélanger S, Yao SQ, Pezacki JP. Activity-based proteome profiling of hepatoma cells during hepatitis C virus replication using protease substrate probes. J. Proteome Res. 9(2), 912-923 (2010).
88. Blais DR, Lyn RK, Joyce MA et al. Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. J. Biol. Chem. 285(33), 25602-25612 (2010).
89. Singaravelu R, Blais DR, McKay CS, Pezacki JP. Activity-based protein profiling of the hepatitis C virus replication in Huh-7 hepatoma cells using a non-directed active site probe. Proteome Sci. 8, 5 (2010).
90. Lu CP, Ren CT, Lai YN et al. Design of a mechanism-based probe for neuraminidase to capture influenza viruses. Angew. Chem. Int. Ed. Engl. 44(42), 6888-6892 (2005).
91. Ovaa H, Kessler BM, Rolén U, Galardy PJ, Ploegh HL, Masucci MG. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl Acad. Sci. USA 101(8), 2253-2258 (2004).
92. Rolén U, Kobzeva V, Gasparjan N et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol. Carcinog. 45(4), 260-269 (2006).
93. Yang PY, Wang M, He CY, Yao SQ. Proteomic profiling and potential cellular target identification of K11777, a clinical cysteine protease inhibitor, in Trypanosoma brucei. Chem. Commun. (Camb.) 48(6), 835-837 (2012).
94. Shi H, Cheng X, Sze SK, Yao SQ. Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe. Chem. Commun. (Camb.) 47(40), 11306-11308 (2011).
95. Ovaa H, Van Swieten PF, Kessler BM et al. Chemistry in living cells: Detection of active proteasomes by a two-step labeling strategy. Angew. Chem. Int. Ed. Engl. 42(31), 3626-3629 (2003).
96. Wright AT, Cravatt BF. Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo. Chem. Biol. 14(9), 1043-1051 (2007).
97. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in smallmolecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 23(10), 1303-1307 (2005).
98. Yang PY, Liu K, Ngai MH, Lear MJ, Wenk MR, Yao SQ. Activity-based proteome profiling of potential cellular targets of Orlistat-an FDA-approved drug with anti-tumor activities. J. Am. Chem. Soc. 132(2), 656-666 (2010).
99. Zeiler E, Korotkov VS, Lorenz-Baath K, Böttcher T, Sieber SA. Development and characterization of improved β-lactonebased anti-virulence drugs targeting ClpP. Bioorg. Med. Chem. 20(2), 583-591 (2012).
100. Böttcher T, Sieber SA. Beta-lactones as specific inhibitors of ClpP attenuate the production of extracellular virulence factors of Staphylococcus aureus. J. Am. Chem. Soc. 130(44), 14400-14401 (2008).
101. Staub I, Sieber SA. Beta-lactams as selective chemical probes for the in vivo labeling of bacterial enzymes involved in cell wall biosynthesis, antibiotic resistance, and virulence. J. Am. Chem. Soc. 130(40), 13400-13409 (2008).
102. Staub I, Sieber SA. Beta-lactam probes as selective chemical-proteomic tools for the identification and functional characterization of resistance associated enzymes in MRSA. J. Am. Chem. Soc. 131(17), 6271-6276 (2009).
103. Wang Z, Gu C, Colby T et al. Beta-lactone probes identify a papain-like peptide ligase in Arabidopsis thaliana. Nat. Chem. Biol. 4(9), 557-563 (2008).
104. Weerapana E, Speers AE, Cravatt BF. Tandem orthogonal proteolysis-activitybased protein profiling (TOP-ABPP) - A general method for mapping sites of probe modification in proteomes. Nat. Protoc. 2(6), 1414-1425 (2007).
105. Speers AE, Cravatt BF. A tandem orthogonal proteolysis strategy for high-content chemical proteomics. J. Am. Chem. Soc. 127(28), 10018-10019 (2005).
106. Berger AB, Vitorino PM, Bogyo M. Activity-based protein profiling: Applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4(6), 371-381 (2004).
107. Blum G, Mullins SR, Keren K et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. 1(4), 203-209 (2005).
108. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3(10), 668-677 (2007).
109. Hu M, Li L, Wu H et al. Multicolor, one- and two-photon imaging of enzymatic activities in live cells with fluorescently quenched activity-based probes (qABPs). J. Am. Chem. Soc. 133(31), 12009-12020 (2011).
110. Nice EC, Rothacker J, Weinstock J, Lim L, Catimel B. Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis. J. Chromatogr. A 1168(1-2), 190-210; discussion 189 (2007).
111. Guiffant D, Tribouillard D, Gug F et al. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol. J. 2(1), 68-75 (2007).
112. Xie N, Huang K, Zhang T et al. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. J. Proteomics 75(3), 725-739 (2012).
113. Gou LT, Tong AP, Chen LJ et al. Comparative plasma membrane-associated proteomics of immortalized human hepatocytes. Biochemistry Mosc. 73(11), 1200-1206 (2008).
114. Sleno L, Emili A. Proteomic methods for drug target discovery. Curr. Opin. Chem. Biol. 12(1), 46-54 (2008).
115. Yamamoto K, Yamazaki A, Takeuchi M, Tanaka A. A versatile method of identifying specific binding proteins on affinity resins. Anal. Biochem. 352(1), 15-23 (2006).
116. Valsasina B, Kalisz HM, Isacchi A. Kinase selectivity profiling by inhibitor affinity chromatography. Expert Rev. Proteomics 1(3), 303-315 (2004).
117. Godl K, Wissing J, Kurtenbach A et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl Acad. Sci. USA 100(26), 15434-15439 (2003).
118. Brehmer D, Greff Z, Godl K et al. Cellular targets of gefitinib. Cancer Res. 65(2), 379-382 (2005).
119. Godl K, Gruss OJ, Eickhoff J et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res. 65(15), 6919-6926 (2005).
120. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell Proteomics 3(5), 490-500 (2004).
121. Bach S, Knockaert M, Reinhardt J et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280(35), 31208-31219 (2005).
122. Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med. 340(17), 1330-1340 (1999).
123. Rix U, Hantschel O, Dürnberger G et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12), 4055-4063 (2007).
124. Hantschel O, Rix U, Schmidt U et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl Acad. Sci. USA 104(33), 13283-13288 (2007).
125. Remsing Rix LL, Rix U, Colinge J et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23(3), 477-485 (2009).
126. Kim DH, Sim T. Chemical kinomics: A powerful strategy for target deconvolution. BMB Rep. 43(11), 711-719 (2010).
127. Bantscheff M, Eberhard D, Abraham Y et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25(9), 1035-1044 (2007).
128. Wu Z, Doondeea JB, Gholami AM et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol. Cell Proteomics 10(12), M111.011635 (2011).
129. Daub H, Olsen JV, Bairlein M et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 31(3), 438-448 (2008).
130. Piggott AM, Karuso P. Quality, not quantity: The role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen. 7(7), 607-630 (2004).
131. Kotake Y, Sagane K, Owa T et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol. 3(9), 570-575 (2007).
132. Bordeleau ME, Matthews J, Wojnar JM et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl Acad. Sci. USA 102(30), 10460-10465 (2005).
133. Wang G, Shang L, Burgett AW, Harran PG, Wang X. Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division. Proc. Natl Acad. Sci. USA 104(7), 2068-2073 (2007).
134. Graves PR, Kwiek JJ, Fadden P et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62(6), 1364-1372 (2002).
135. Wang ZY. Arsenic compounds as anticancer agents. Cancer Chemother. Pharmacol. 48(Suppl. 1), S72-S76 (2001).
136. Zhang XW, Yan XJ, Zhou ZR et al. Arsenic trioxide controls the fate of the PMLRARalpha oncoprotein by directly binding PML. Science 328(5975), 240-243 (2010).
137. Diggle GE. Thalidomide: 40 years on. Int. J. Clin. Pract. 55(9), 627-631 (2001).
138. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H. Development and application of high-performance affinity beads: Toward chemical biology and drug discovery. Chem. Rec. 9(1), 66-85 (2009).
139. Ito T, Ando H, Suzuki T et al. Identification of a primary target of thalidomide teratogenicity. Science 327(5971), 1345-1350 (2010).
140. Saxena C, Zhen E, Higgs RE, Hale JE. An immuno-chemo-proteomics method for drug target deconvolution. J. Proteome Res. 7(8), 3490-3497 (2008).
141. Saxena C, Bonacci TM, Huss KL, Bloem LJ, Higgs RE, Hale JE. Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool. J. Proteome Res. 8(8), 3951-3957 (2009).
142. Hahn R, Berger E, Pflegerl K, Jungbauer A. Directed immobilization of peptide ligands to accessible pore sites by conjugation with a placeholder molecule. Anal. Chem. 75(3), 543-548 (2003).
143. Fischer JJ, Michaelis S, Schrey AK et al. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs. Toxicol. Sci. 113(1), 243-253 (2010).
144. Aye TT, Mohammed S, Van den Toorn HW et al. Selectivity in enrichment of cAMPdependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins. Mol. Cell Proteomics 8(5), 1016-1028 (2009).
145. Hensley K, Christov A, Kamat S et al. Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. J. Neurosci. 30(8), 2979-2988 (2010).
146. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 3(1), 33-44 (2009).
147. Griffith EC, Su Z, Turk BE et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4(6), 461-471 (1997).
148. Budzikiewicz H, Grigsby RD. Mass spectrometry and isotopes: A century of research and discussion. Mass Spectrom. Rev. 25(1), 146-157 (2006).
149. Adam GC, Sorensen EJ, Cravatt BF. Chemical strategies for functional proteomics. Mol. Cell Proteomics 1(10), 781-790 (2002).
150. Ratcliffe SJ, Yi T, Khandekar SS. Synthesis and characterization of 5'-p-fluorosulfonylbenzoyl-2' (or 3')-(biotinyl)adenosine as an activity-based probe for protein kinases. J. Biomol. Screen. 12(1), 126-132 (2007).
151. Li GD. Plasmodium falciparum chloroquine resistance marker protein (Pfcrmp) may be a chloroquine target protein in nucleus. Med. Hypotheses 68(2), 332-334 (2007).